ALTIG ANTHONY E 4

What Happened Anthony E. Altig, a director of Assembly Biosciences (ASMB), received a derivative award on 2026-06-04 consisting of options covering 8,000 shares. The reported acquisition price is $0.00 (grant of stock options), so no cash was paid by the insider at grant. This is a compensation grant (neutral signal) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-04; filing date: 2026-06-05 (timely).
• Transaction type: Grant/Award (derivative stock option); amount: 8,000 underlying shares; reported acquisition price: $0.00.
• Vesting: Per footnote, options vest (assuming continuous service) upon the earlier of (1) June 4, 2027, or (2) the issuer’s 2027 annual meeting of stockholders.
• Shares owned after transaction: Not stated in the filing.
• Filing accession: 0001193125-26-259697. No indication of a 10b5-1 plan, cashless exercise, tax-withholding sale, or late filing.

Context This was an option grant — a common form of executive/director compensation — which gives the holder the right to buy shares in the future if and when the options vest and are exercised. It does not represent an immediate purchase of shares or an immediate sale, and therefore should be interpreted as a compensation event rather than an explicit buy/sell market signal.